• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy and medication are not effective for a lot of patients suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform for digital devices that transforms passively acquired sensor data from smartphones into customized micro-interventions to improve mental health. We examined the most effective-fitting personalized ML models to each person, using Shapley values to determine their feature predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

Depression is among the world's leading causes of mental illness.1 However, only about half of those who have the disorder receive treatment1. To improve the outcomes, clinicians need to be able to recognize and treat patients with the highest probability of responding to specific treatments.

Personalized atypical depression treatment treatment is one way to do this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit most from certain treatments. They make use of mobile phone sensors and a voice assistant incorporating artificial intelligence, and other digital tools. Two grants were awarded that total more than $10 million, they will make use of these technologies to identify the biological and behavioral factors that determine response to antidepressant medications and psychotherapy.

To date, the majority of research on factors that predict depression treatment effectiveness has centered on the sociodemographic and clinical aspects. These include demographics like age, gender, and education, as well as clinical characteristics such as symptom severity and comorbidities, as well as biological markers.

While many of these variables can be predicted from information in Medical treatment For depression records, only a few studies have used longitudinal data to study predictors of mood in individuals. Many studies do not take into consideration the fact that moods vary significantly between individuals. Therefore, it is critical to create methods that allow the recognition of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can systematically identify different patterns of behavior and emotions that are different between people.

In addition to these modalities, the team created a machine learning algorithm to model the changing variables that influence each person's mood. The algorithm blends these individual differences into a unique "digital phenotype" for each participant.

This digital phenotype was linked to CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is the most common cause of disability in the world1, however, it is often misdiagnosed and untreated2. In addition the absence of effective treatments and stigma associated with depressive disorders prevent many from seeking treatment.

To assist in individualized treatment, it is essential to determine the predictors of symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only detect a few characteristics that are associated with depression.

Machine learning is used to blend continuous digital behavioral phenotypes of a person captured by smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory the CAT-DI) together with other predictors of severity of symptoms could increase the accuracy of diagnostics and the effectiveness of treatment for depression. Digital phenotypes can be used to are able to capture a variety of distinct actions and behaviors that are difficult to record through interviews, and also allow for continuous and high-resolution measurements.

The study involved University of California Los Angeles students who had mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment based on the degree of their depression. Those with a CAT-DI score of 35 65 students were assigned online support with the help of a coach. Those with a score 75 patients were referred to in-person psychotherapy.

Participants were asked a set of questions at the beginning of the study concerning their demographics and psychosocial characteristics. The questions asked included age, sex, and education as well as financial status, marital status as well as whether they divorced or not, the frequency of suicidal thoughts, intent or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used to assess the severity of depression treatment in uk-related symptoms on a scale from 100 to. The CAT-DI test was carried out every two weeks for participants who received online support, and weekly for those who received in-person assistance.

Predictors of the Reaction to Treatment

A customized treatment for depression is currently a top research topic and many studies aim at identifying predictors that enable clinicians to determine the most effective medication for each patient. Particularly, pharmacogenetics can identify genetic variants that determine how the body metabolizes antidepressants. This lets doctors choose the medications that will likely work best drug to treat anxiety and depression for each patient, reducing time and effort spent on trials and errors, while eliminating any adverse consequences.

Another approach that is promising is to build models of prediction using a variety of data sources, including clinical information and neural imaging data. These models can be used to determine which variables are the most predictive of a specific outcome, like whether a medication will help with symptoms or mood. These models can be used to determine the patient's response to treatment that is already in place, allowing doctors to maximize the effectiveness of their treatment currently being administered.

A new type of research employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables to improve predictive accuracy. These models have been shown to be useful in predicting treatment outcomes like the response to antidepressants. These methods are becoming popular in psychiatry, and it is likely that they will become the standard for the future of clinical practice.

In addition to ML-based prediction models, research into the underlying mechanisms of depression is continuing. Recent findings suggest that depression is related to dysfunctions in specific neural networks. This suggests that individual depression treatment will be focused on treatments that target these circuits in order to restore normal function.

Internet-delivered interventions can be an effective method to achieve this. They can provide an individualized and tailored experience for patients. One study discovered that a web-based treatment was more effective than standard treatment in reducing symptoms and ensuring the best quality of life for patients with MDD. A controlled, randomized study of an individualized treatment for depression showed that a significant percentage of participants experienced sustained improvement and had fewer adverse consequences.

Predictors of adverse effects

In the treatment of depression, the biggest challenge is predicting and identifying which antidepressant medication will have very little or no negative side effects. Many patients are prescribed a variety drugs before they find a drug that is effective and tolerated. Pharmacogenetics provides an exciting new method for an efficient and specific approach to choosing antidepressant medications.

There are a variety of predictors that can be used to determine which antidepressant should be prescribed, including gene variations, patient phenotypes such as ethnicity or gender, and co-morbidities. However finding the most reliable and accurate predictive factors for a specific treatment is likely to require randomized controlled trials of much larger samples than those that are typically part of clinical trials. This is due to the fact that it can be more difficult to determine moderators or interactions in trials that only include a single episode per person rather than multiple episodes over a long period of time.

In addition, predicting a patient's response will likely require information on comorbidities, symptom profiles and the patient's own perception of effectiveness and tolerability. Presently, only a handful of easily assessable sociodemographic and clinical variables are believed to be reliably associated with response to MDD, such as age, gender, race/ethnicity and SES BMI and the presence of alexithymia, and the severity of depressive symptoms.

Many issues remain to be resolved when it comes to the use of pharmacogenetics for depression treatment. First, a clear understanding of the underlying genetic mechanisms is needed as well as a clear definition of what constitutes a reliable predictor for treatment response. Ethics like privacy, and the responsible use genetic information are also important to consider. In the long-term pharmacogenetics can provide an opportunity to reduce the stigma that surrounds mental health treatment and to improve the outcomes of those suffering with depression. However, as with any other psychiatric treatment, careful consideration and planning is required. For now, the best method is to provide patients with various effective depression medication options and encourage them to talk openly with their doctors about their experiences and concerns.